Breast cancer: questions for future trials.

[1]  T. Davidson.  Why I favour axillary node clearance in the management of breast cancer , 1995 .

[2]  L. Tabár,et al.  Breast cancer treatment and natural history: new insights from results of screening , 1992, The Lancet.

[3]  Donald L. Morton,et al.  Lymphatic Mapping and Sentinel Lymphadenectomy for Breast Cancer , 1994, Annals of surgery.

[4]  A. D. Schryver,et al.  Systemic treatment of early breast-cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women: 1 , 1992 .

[5]  Mike Clarke,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992 .

[6]  M. J. van de Vijver,et al.  Ductal carcinoma in situ: a proposal for a new classification. , 1994, Seminars in diagnostic pathology.

[7]  D. Weaver,et al.  Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. , 1993, Surgical oncology.

[8]  M. Greenall.  Why I favour axillary node sampling in the management of breast cancer , 1995 .

[9]  M. Baum,et al.  New approach for recruitment into randomised controlled trials , 1993, The Lancet.

[10]  D. F. Easton,et al.  Genetic linkage analysis in familial breast and ovarian cancer: Results from 214 families , 1993 .

[11]  S. Seal,et al.  Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. , 1994, Science.

[12]  D. Easton,et al.  Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. , 1993, American journal of human genetics.